| Wilms_ tumor suppressor gene (WT1) as a target gene of SRY function in a mouse ES cell line transfected with SRY. | None |
| Why is the oncogene WT1 in the developing kidney and what is it doing there?. | kidney, |
| A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. | kidney, |
| The zinc finger domain of Wilms tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells. | breast, |
| Peptide epitopes from the Wilms tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. | mesothelioma, |
| The expression of WT1 is increased more in HCC than in non-tumour tissues. Overexpressed WT1 was associated with tumour growth, and resulted in a worsening prognosis of HCC. WT1 overexpression might contribute to oncogenic potential. | liver, |
| Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. | leukemia, |
| These data suggest that miR-15a/16-1 may function as a tumor suppressor to regulate leukemic cell proliferation potentially by down-regulating the WT1 oncogene. | leukemia, |
| an oncogenic role of WT1 and a possible relation between WT1 and progression of breast cancer | breast, |
| Wilms tumor 1 gene (WT1) is overexpressed and provides an oncogenic function in pediatric nephroblastomas harboring the wild-type WT1. | pediatric,nephroblastoma, |
| WT1 modulates cFLIP, FADD and NF-kappaB, and has an anti-apoptotic role in hepatocellular carconoma. This mechanism of action of WT1 could be related to the tumor growth and oncogenic potential of HCC. | liver, |
| WT1 is an oncogene and promotes NSCLC cell proliferation by up-regulating Cyclin D1 and p-pRb expression | lung, |
| WT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo. | lung, |
| these data suggest that WT1 functions as an oncogene in leukemia cells, and one important mechanism is regulation of the Wnt/beta-catenin pathway | leukemia, |
| Role of the Wilms tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms. | leukemia, |
| WT1 (and p63) act as oncogenes in squamous cell carcinoma of the head and neck, affecting multiple genes involved in cancer cell growth. | HNSC, |
| Novel oncogenic mutations in the WT1 Wilms tumor suppressor gene: a t(11;22) fuses the Ewing s sarcoma gene, EWS1, to WT1 in desmoplastic small round cell tumor. | sarcoma, |
| WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. | None |
| Wilms tumor gene WT1: its oncogenic function and clinical application. | None |
| Cyclin E is a target of WT1 transcriptional repression. | None |